V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016738 | 160016430 | 1.63 | 74.8 | null | 2020-07-25 | 2020-07-26 | EW EuroEwing 2012 Arm B IE | null | null | DOXORUBICIN + IFOSFAMIDE | 101198025 |
| 160016741 | 160016431 | 1.73 | 80.55 | Curative (C) | 2017-03-22 | 2017-04-22 | Carboplatin + Liposomal Doxorubicin | N | N | ERIBULIN | 101717234 |
| 160016745 | 160016432 | 1.81 | 63.5 | null | 2020-01-17 | 2020-01-17 | Rucaparib | N | null | BLEOMYCIN | 101560703 |
| 160016747 | 160016433 | 1.76 | 42.5 | Palliative (P) | 2017-03-17 | 2017-03-28 | Etoposide + Ifosfamide (5 days) | 02 | N | VINCRISTINE | 100820783 |
| 160016749 | 160016434 | 1.91 | null | Neo-adjuvant (N) | 2018-01-30 | 2019-03-22 | GEMCITABINE | 02 | N | LENALIDOMIDE | 100080250 |
| 160016752 | 160016435 | 0 | 86 | Curative (C) | 2018-03-04 | 2018-03-15 | Olaratumab | 02 | Y | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101614131 |
| 160016758 | 160016436 | 1.61 | 67.7 | null | 2015-05-07 | 2015-05-28 | ATOMIC-MESO TRIAL | 02 | null | CONFIRM TRIAL | 100457650 |
| 160016764 | 160016437 | 1.7 | 49.3 | null | 2020-02-08 | 2021-05-22 | Carboplatin+Fluorouracil 4 or 5 day | 01 | null | DINUTUXIMAB BETA | 100113762 |
| 160016777 | 160016438 | null | 53.4 | Palliative (P) | 2020-04-13 | 2020-04-13 | Cyclophosphamide + Vincristine | 02 | N | PAZOPANIB | 101479368 |
| 160016779 | 160016439 | 1.86 | 73.1 | null | 2018-08-28 | 2018-09-16 | Ifosfamide | 02 | null | NEMO TRIAL | 100909788 |
| 160016784 | 160016441 | 1.62 | 41.6 | null | null | null | Gemcitabine 1000mg/m2 D1 8 15 | 01 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101548082 |
| 160016795 | 160016442 | 1.6 | 93.7 | null | 2017-06-26 | 2017-07-24 | IVADo | N | null | EURO-EWING | 100985487 |
| 160016796 | 160016443 | 0 | 96 | Palliative (P) | 2019-05-08 | 2019-05-15 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101456359 |
| 160016802 | 160016444 | 0 | 90 | Disease modification (D) | 2018-03-18 | 2018-04-09 | NB HRNBL-1 Isotretinoin | N | N | GEMCITABINE | 101818931 |
| 160016803 | 160016445 | 0 | 19.6 | null | 2018-10-20 | 2018-10-29 | ETOPOSIDE | 02 | null | IPM | 101513425 |
| 160016808 | 160016446 | 1.68 | 48.9 | Palliative (P) | 2019-03-23 | 2019-03-23 | VIA (Ifos 1.5g/m2) | 02 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 101382768 |
| 160016809 | 160016447 | 1.71 | 65.4 | Curative (C) | 2021-05-23 | 2021-05-30 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | EW EUROEWING 2012 ARM B VDC | 100670122 |
| 160016810 | 160016448 | 1.65 | 56.7 | Neo-adjuvant (N) | 2017-11-13 | 2017-11-19 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101402124 |
| 160016811 | 160016449 | 1.7 | 130.2 | 03 | null | null | PEMBROLIZUMAB | 02 | null | CARBOPLATIN + DOCETAXEL | 100428216 |
| 160016818 | 160016450 | 0 | 8.6 | Curative (C) | 2019-09-28 | 2019-09-28 | NB HRNBL-1 COJEC Ind COURSE B | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100881694 |
| 160016819 | 160016451 | 1.77 | 55.8 | null | 2018-04-13 | 2018-04-13 | Pazopanib | 02 | null | NOT MATCHED | 101758856 |
| 160016826 | 160016452 | 1.62 | 0 | null | 2021-10-05 | 2021-10-25 | EW EuroEwing 2012 Arm B VDC/IE | Y | null | IMATINIB | 101137397 |
| 160016827 | 160016453 | null | null | Palliative (P) | 2018-02-24 | 2018-06-06 | MELPHALAN | 02 | N | GEMCITABINE | 100174492 |
| 160016834 | 160016454 | 1.61 | 77.4 | null | 2017-05-29 | 2017-10-28 | Ifosfamide | 02 | null | CARBOPLATIN + VINORELBINE | 101549790 |
| 160016838 | 160016455 | 1.63 | 96.6 | Adjuvant (A) | 2016-08-03 | 2016-09-04 | Trastuzumab emtansine (Kadcyla) 1st | N | N | ETOPOSIDE + IFOSFAMIDE | 100101467 |
| 160016841 | 160016456 | 1.6 | 93.9 | null | null | 2019-02-20 | Olaratumab | 01 | null | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 101515893 |
| 160016844 | 160016457 | 0 | 63.9 | null | 2016-12-29 | 2016-12-30 | Niraparib | 02 | null | NIRAPARIB | 100517306 |
| 160016847 | 160016458 | 1.79 | 75.7 | null | 2019-01-28 | 2019-02-11 | Doxorubicin chemoembolisation | 02 | null | STS RHABDO RMS 2005 2ND TOPO CARBO | 101440899 |
| 160016850 | 160016459 | 1.8 | 81 | Neo-adjuvant (N) | 2017-12-22 | 2017-12-28 | PEMBROLIZUMAB | 02 | N | ETOPOSIDE + IFOSFAMIDE | 101449381 |
| 160016852 | 160016460 | 0 | 15.8 | Curative (C) | 2016-11-08 | 2016-11-11 | null | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 100332645 |
| 160016855 | 160016461 | 1.83 | 80 | Curative (C) | 2015-05-28 | 2015-06-05 | ECX | 02 | N | DINUTUXIMAB BETA | 101297903 |
| 160016864 | 160016462 | 1.66 | 71 | Palliative (P) | 2017-07-08 | 2018-02-09 | EW EuroEwing 2012 Arm A VAI | 01 | N | NOT MATCHED | 100026642 |
| 160016865 | 160016463 | 1.75 | 85.9 | Palliative (P) | 2018-10-13 | 2018-10-29 | Dinutuximab Beta | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100784015 |
| 160016868 | 160016464 | 1.8 | 19.8 | Palliative (P) | 2020-04-02 | 2020-04-10 | DACARBAZINE + GEMCITABINE | 02 | N | OLAPARIB | 101197738 |
| 160016869 | 160016465 | null | 75.8 | null | 2019-01-04 | 2019-02-11 | Lenalidomide 25mg (Cycle 1 to 25) | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100954955 |
| 160016877 | 160016466 | 1.64 | 127 | Neo-adjuvant (N) | 2017-05-17 | 2017-11-29 | IPM | 02 | N | NIRAPARIB | 100841815 |
| 160016885 | 160016468 | 1.65 | 68.8 | null | 2019-04-16 | 2019-04-16 | Irinotecan + Temozolomide | null | null | ETOPOSIDE | 101028116 |
| 160016887 | 160016469 | 0 | 55.6 | Palliative (P) | 2016-07-27 | 2017-03-06 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CARBOPLATIN + LIPOSOMAL DOX | 100948053 |
| 160016889 | 160016470 | 1.73 | 80.5 | Palliative (P) | 2017-03-04 | 2017-03-18 | Cyclophosphamide PO +Vinorelbine IV | 02 | N | NB HRNBL-1 ISOTRETINOIN | 100828540 |
| 160016893 | 160016471 | 1.64 | 51.6 | null | 2019-03-10 | 2019-03-16 | Ifosfamide | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100280433 |
| 160016895 | 160016472 | 1.62 | 68.2 | Palliative (P) | 2018-09-10 | 2018-09-10 | VAI (Ifos 3g/m2) | 01 | N | ABEMACICLIB + FULVESTRANT | 100586589 |
| 160016901 | 160016473 | null | 98.6 | Palliative (P) | 2020-11-21 | 2022-05-06 | CARBOPLATIN + GEMCITABINE | 02 | N | RMS 2005 TRIAL | 101762420 |
| 160016906 | 160016474 | null | 73.3 | null | 2019-11-06 | 2019-11-28 | PROMISE-MESO TRIAL | 02 | null | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101145806 |
| 160016915 | 160016475 | 0 | 63.5 | null | 2022-05-08 | 2022-05-26 | EW EuroEwing 2012 Arm A VAC | null | null | NIRAPARIB | 101636097 |
| 160016921 | 160016476 | null | 129.6 | Palliative (P) | 2021-06-11 | 2021-06-11 | ETOP 13-18 BEAT-meso Trial | 02 | N | CAPECITABINE | 100601969 |
| 160016923 | 160016477 | 1.82 | 59.8 | null | 2016-06-16 | 2016-07-21 | EW EuroEwing 2012 Arm B IE | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + OBINUTUZUMAB + VINCRISTINE | 100612536 |
| 160016928 | 160016478 | 1.09 | 15.05 | null | 2016-11-02 | 2016-11-12 | Doxorubicin + Ifosfamide | 02 | null | IFOSFAMIDE | 100225062 |
| 160016932 | 160016479 | 1.52 | 90.3 | Neo-adjuvant (N) | 2018-01-25 | 2018-03-15 | Etoposide + Ifosfamide (5 days) | 02 | N | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 100082815 |
| 160016940 | 160016480 | 1.7 | 27 | null | 2019-07-24 | 2019-09-02 | EW EuroEwing 2012 Arm B IE | 02 | null | TOPOTECAN | 100527877 |
| 160016946 | 160016481 | 1.69 | 72 | Adjuvant (A) | 2019-06-17 | 2019-06-30 | NB Low/Intermed risk guidelines CADO | 02 | null | CISPLATIN + ETOPOSIDE | 100193304 |